Announcing NeuroBlu v3.1 with ANSA Integration for Enhanced Pharma and HEOR Research.
We are excited to introduce NeuroBlu v3.1, featuring the latest 23R2 database updates and the integration of the ANSA (Adult Needs and Strengths Assessment) and the AIMS (The Abnormal Involuntary Movement Scale) scales. Here is what is new and improved:
What is New:
Integration of ANSA:
Provides valuable data for RWD research and potential use cases, including tracking patient progress over time, identifying social determinants of health, assessing treatment effectiveness, and developing targeted interventions.
Integration of AIMS:
AIMS (The Abnormal Involuntary Movement Scale) is an assessment to . measure the level of dyskinesias in patients taking neuroleptic medications.
The scale was developed by the Psychopharmacology Research Branch of the National Institute of Mental Health, and is widely used to assess tardive dyskinesia in clinical trials of antipsychotic medications. In a clinical setting it may be used for screening and monitoring of symptoms, for patients on antipsychotic medications.
NeuroBlu Database 23R2 Updates:
What has Improved:
We encourage you to leverage the latest NeuroBlu v3.1 and take advantage of the ANSA and AIMS integration to improve your data-driven decision-making and analysis in pharma and HEOR research!